Riskpilot← Back to searchSign inGet full accessMONTEBELLO DIAGNOSTICS AS
ASActiveOrg 9941711273. Etg Ole Deviks Vei 16A, 0666 OsloWholesale of pharmaceutical and medical goods · NACE 4646Est. 20098 employeeswww.montebello.no
Revenue 2025
NOK 229,9M
-1% vs 2024
EBITDA margin
17.4%
+1% vs 2024
Equity ratio
31.4%
Financial strength
Net profit 2025
NOK 30,5M
-3% vs 2024
| Revenue | NOK 229,9M | -1% |
| EBITDA | NOK 39,9M | +1% |
| Net profit | NOK 30,5M | -3% |
| Total assets | NOK 109,7M | -1% |
| Equity | NOK 34,5M | +0% |
| Employees | 8 | — |
Legal name
MONTEBELLO DIAGNOSTICS AS
Org number
994171127
Legal form
Aksjeselskap
NACE code
4646 · Wholesale of pharmaceutical and medical goods
Founded
4. juni 2009
Share capital
NOK 100 000
Employees
8 (FTE)
VAT registered
Yes
Audit selected
No
Last report
2025-12-31
Financial year
January – December
Signatory rights
Styrets leder alene.
Company purpose
Drive handel innen sykehusprodukter, samt delta i andre virksomheter med samme eller lignende virksomhet.
Address
3. Etg Ole Deviks Vei 16A, 0666 Oslo
Phone
+4722141490
Website
www.montebello.no
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 12 712 | 18 157 | 20 509 | 24 371 | 25 239 | 28 917 | 32 855 | 44 091 | 68 072 | 75 003 | 85 392 | 160 861 | 277 837 | 175 997 | 146 132 | 231 668 | 229 851 |
| Staff expenses | −2 250 | −4 018 | −4 704 | −5 222 | −5 329 | −5 885 | −5 936 | −6 176 | −7 832 | −9 976 | −7 917 | −8 889 | −8 605 | −7 913 | −8 282 | −10 434 | −11 161 |
| EBITDA | 3 134 | 3 378 | 3 163 | 3 645 | 3 423 | 4 041 | 3 168 | 1 966 | 7 051 | −939 | 6 816 | 24 633 | 76 562 | 36 065 | 13 001 | 39 676 | 39 925 |
| Depreciation & amort. | −366 | −618 | −560 | −575 | −568 | −305 | −113 | −172 | −177 | −148 | −501 | −942 | −960 | −953 | −1 284 | −1 258 | −838 |
| EBIT | 2 768 | 2 760 | 2 603 | 3 071 | 2 855 | 3 736 | 3 055 | 1 794 | 6 874 | −1 087 | 6 314 | 23 691 | 75 602 | 35 112 | 11 717 | 38 418 | 39 087 |
| Net financials | −44 | −76 | −121 | −49 | −27 | 5 | 18 | −70 | −980 | −487 | −261 | 401 | 343 | 152 | −1 199 | 1 433 | 80 |
| Profit before tax | 2 725 | 2 684 | 2 482 | 3 022 | 2 829 | 3 741 | 3 073 | 1 724 | 5 894 | −1 574 | 6 053 | 24 092 | 75 945 | 35 264 | 10 518 | 39 851 | 39 167 |
| Tax | 774 | 778 | 735 | 845 | 805 | 1 015 | 864 | 462 | 1 440 | −332 | 1 350 | 5 325 | 16 715 | 7 799 | 2 579 | 8 496 | 8 669 |
| Net profit | 1 950 | 1 907 | 1 747 | 2 177 | 2 024 | 2 726 | 2 209 | 1 262 | 4 455 | −1 242 | 4 703 | 18 767 | 59 230 | 27 465 | 7 939 | 31 355 | 30 498 |
| Item | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | 11 209 | 10 666 | 9 981 | 7 807 | 8 148 | 10 274 | 12 578 | 16 545 | 24 902 | 21 440 | 30 004 | 62 599 | 143 029 | 70 981 | 72 772 | 110 576 | 109 718 |
| Equity | 2 052 | 1 659 | 1 281 | 1 308 | 1 332 | 1 707 | 3 917 | 4 179 | 4 634 | 3 392 | 6 095 | 18 185 | 26 415 | 20 180 | 18 118 | 34 473 | 34 471 |
| Long-term debt | 4 369 | 2 944 | 2 185 | 460 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Short-term debt | 4 789 | 6 063 | 6 515 | 6 039 | 6 816 | 8 567 | 8 661 | 12 366 | 20 268 | 18 049 | 23 909 | 44 414 | 116 614 | 50 801 | 54 653 | 76 103 | 75 246 |
| Total debt | 9 158 | 9 007 | 8 700 | 6 500 | 6 816 | 8 567 | 8 661 | 12 366 | 20 268 | 18 049 | 23 909 | 44 414 | 116 614 | 50 801 | 54 653 | 76 103 | 75 246 |
EBITDA margin
17.4%
This company
15.8%
Market median
+10% vs market
20092025
Equity ratio
31.4%
This company
38.2%
Market median
+18% vs market
20092025
Return on equity
88.5%
This company
18.4%
Market median
+381% vs market
20092025
Net profit margin
13.3%
This company
8.1%
Market median
+64% vs market
20092025
Asset turnover
2.09×
This company
1.12×
Market median
+87% vs market
20092025
Debt / equity
2.18×
This company
0.62×
Market median
-252% vs market
20092025
- Annual report 2025Filed via Brønnøysundsregistrene · Period 2025-01-01 – 2025-12-31
- Annual report 2024Filed via Brønnøysundsregistrene · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Brønnøysundsregistrene · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Brønnøysundsregistrene · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Brønnøysundsregistrene · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Brønnøysundsregistrene · Period 2020-01-01 – 2020-12-31
- Annual report 2019Filed via Brønnøysundsregistrene · Period 2019-01-01 – 2019-12-31
- Annual report 2018Filed via Brønnøysundsregistrene · Period 2018-01-01 – 2018-12-31
- Annual report 2017Filed via Brønnøysundsregistrene · Period 2017-01-01 – 2017-12-31
- Annual report 2016Filed via Brønnøysundsregistrene · Period 2016-01-01 – 2016-12-31
- Annual report 2015Filed via Brønnøysundsregistrene · Period 2015-01-01 – 2015-12-31
- Annual report 2014Filed via Brønnøysundsregistrene · Period 2014-01-01 – 2014-12-31
- Annual report 2013Filed via Brønnøysundsregistrene · Period 2013-01-01 – 2013-12-31
- Annual report 2012Filed via Brønnøysundsregistrene · Period 2012-01-01 – 2012-12-31
- Annual report 2011Filed via Brønnøysundsregistrene · Period 2011-01-01 – 2011-12-31
- Annual report 2010Filed via Brønnøysundsregistrene · Period 2010-01-01 – 2010-12-31
- Annual report 2009Filed via Brønnøysundsregistrene · Period 2009-06-01 – 2009-12-31
No data on file.
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
| Board of Directors | 2023 | — | — | |
| Board of Directors | 2021 | — | — | |
| Board of Directors | 2021 | — | — |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
Armile As | Company | 65.0% | 65.0% | 2024 |
Montebello Holding As | Company | 10.0% | 10.0% | 2024 |
| Individual | 10.0% | 10.0% | 2024 | |
| Individual | 10.0% | 10.0% | 2024 | |
| Individual | 5.0% | 5.0% | 2024 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
MONTEBELLO DIAGNOSTICS AS 
APRIMEO DIAGNOSTICS NORDIC ASBoard members of MONTEBELLO DIAGNOSTICS AS also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Halldor Christen Tjoflaat | Board of Directors | 0 companies |
| Alf Gervin | Board of Directors | 0 companies |
| Ingrid Frivold Brobakk | Board of Directors | 0 companies |